New York, September 30, 2024 - PRISM MarketView - Klotho Neurosciences, Inc. (Nasdaq: KLTO), a leader in developing therapies for neurodegenerative diseases and promoting healthy longevity, announced a pivotal milestone: Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board.
Dr. Langer is an MIT professor and one of the most cited researchers in history. His pioneering work in drug delivery systems and tissue engineering has earned him numerous accolades, including the National Medal of Science. As a co-founder of Moderna, he played a pivotal role in developing mRNA-based therapeutics, including the groundbreaking COVID-19 vaccine. His involvement with Klotho Neurosciences underscores his confidence in the company’s mission to address unmet medical needs in ALS, Alzheimer’s and Parkinson’s diseases.
“I am excited to collaborate with the team at Klotho Neurosciences as they explore the therapeutic potential of the Klotho protein in combating neurodegenerative conditions. The company is working on something incredibly promising, and I’m eager to support their efforts.”
Dr. Robert Langer
Klotho Neurosciences is strategically advancing its focus on neurodegenerative diseases and healthy aging. Its primary candidate targets ALS, with the global ALS market valued at $667.3 million and growing. Additionally, Klotho is developing therapies for Alzheimer’s and Parkinson’s using its proprietary s-KL gene therapy platform. The global Alzheimer’s therapeutics market was valued at $4.05 billion in 2022 and is expected to grow at a CAGR of 19.99% from 2023 to 2030. Collaborating with “Blue Zone” researchers, Klotho aims to identify biomarkers for healthy aging and develop early detection methods to enhance patient outcomes.
About Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc., formerly ANEW MEDICAL, INC., is a Nasdaq-listed pharmaceutical company with the ticker symbol KLTO. The company specializes in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and know-how to develop cutting-edge protein, gene and cell therapies to treat age-related pathologies such as ALS, Alzheimer’s and Parkinson’s disease, multiple sclerosis and rare neurodegenerative diseases. The company is managed by a team of individuals and advisors who are highly experienced in medical product development and commercialization of medical products. For additional information, please visit www.klothoneuro.com.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities